Plural Amino Nitrogens Patents (Class 514/673)
-
Patent number: 11890262Abstract: A composition and method for treatment of brittle, broken, cracked or otherwise damaged nail and hoof plates. The composition is an aqueous-organic medium containing a non-covalent complex of a diamine and an organic acid or an aqueous-organic medium with a diamine alone.Type: GrantFiled: July 10, 2018Date of Patent: February 6, 2024Assignee: WELLA OPERATIONS US, LLCInventors: Elizabeta Pavlovic, Sunan Yuvavanich
-
Publication number: 20140294799Abstract: The composition includes, per gram of composition, less than 600, in particular less than 400 picomoles of biologically active polyamines, for use in the prevention or treatment of radiotherapy-induced pathologies of the skin or mucous membranes in a patient, in particular a human or an animal.Type: ApplicationFiled: August 30, 2012Publication date: October 2, 2014Applicant: NUTRIALYS MEDICAL NUTRITION SAInventors: Bernard Cipolla, Xavier Artignan
-
Patent number: 8834943Abstract: The present invention features compositions comprising at least one compound of the formula I or formula II: wherein R1, R2, R3, R4, and R5 independently, are selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 hydroxyalkyl, or a cosmetically acceptable salt thereof, and the use thereof.Type: GrantFiled: November 30, 2010Date of Patent: September 16, 2014Assignee: Johnson & Johnson Consumer Companies, Inc.Inventors: Michael Southall, Katharine Martin, Phyllis Mitchell, Menas Kizoulis, Neena Tierney, Elvin R. Lukenbach, Binoy K. Bordoloi
-
Patent number: 8772341Abstract: Germicidal compositions containing one or more N,N-bis(3-aminopropyl) C6-C18 alkyl amines, such as N,N-bis(3-aminopropyl)dodecylamine, and methods of using the compositions for treatment or prevention of infectious hoof diseases are disclosed. The germicidal compositions remain active in the presence of manure, which eliminates the need to pre-clean the hooves before use, and have particular utility for treating or preventing papillomatous digital dermatitis, interdigital phlegmon, interdigital dermatitis, laminitis, white line disease, heel erosion and other hoof diseases.Type: GrantFiled: September 10, 2007Date of Patent: July 8, 2014Assignee: DeLaval Holding ABInventors: Chris Foret, Alex Skender, Thomas C. Hemling
-
Publication number: 20140140932Abstract: The present disclosure provides functionalized magnetic nanoparticles (MNPs) comprising a functional group that binds to ?-amyloid deposits and/or neurofibrillary tangles. The present disclosure provides compositions comprising the functionalized MNPs, and methods of using the functionalized MNPs in imaging ?-amyloid deposits and neurofibrillary tangles.Type: ApplicationFiled: April 4, 2012Publication date: May 22, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventor: Masoud Akhtari
-
Patent number: 8729133Abstract: This invention relates to a process of treating/affecting cancers that are particularly susceptible to radiation therapy by administering to a host in need of such treatment an amino acid and radiation therapy.Type: GrantFiled: February 14, 2007Date of Patent: May 20, 2014Assignee: Cornell UniversityInventor: Leandro Carlos A Cerchietti
-
Patent number: 8728504Abstract: A process for solubilizing hydrophobic active ingredients in aqueous medium, which comprises using, as an assistant, at least one hyperbranched polymer (A) which is obtainable by reacting at least one hyperbranched polymeric compound having at least one primary or secondary amino group per molecule (a), selected from (a1) hyperbranched polyamides and (a2) hyperbranched polyureas, with (b) at least one mono-, di- or oligosaccharide.Type: GrantFiled: February 4, 2011Date of Patent: May 20, 2014Assignee: BASF SEInventors: Bernd Bruchmann, Holger Türk, Daniel Schönfelder, Monika Haberecht, Dietmar Appelhans, Victor Boyko
-
Publication number: 20140107218Abstract: The invention provides novel methods for maintaining eye health and ameliorating ophthalmic maladies in animals by administering to the animals an ophthalmic malady ameliorating amount of one or more polyamines. Generally, the polyamines are administered to the animals in amounts of from about 1 to about 200 mg/kg/day to ameliorate maladies such as cataracts and cloudy eye.Type: ApplicationFiled: October 14, 2013Publication date: April 17, 2014Applicant: NESTEC SAInventors: Scott Sherrill, Wei Wang
-
Publication number: 20140056951Abstract: Methods of treating or reducing biofilms, treating a biofilm-related disorder, and preventing biofilm formation using polyamines is described.Type: ApplicationFiled: November 4, 2013Publication date: February 27, 2014Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Richard LOSICK, Illana KOLODKIN-GAL, Jon CLARDY, Shugeng CAO, Matt CABEEN, Roberto KOLTER, Liraz CHAI, Thomas BÖTTCHER
-
Publication number: 20140056952Abstract: Methods of treating or reducing biofilms, treating a biofilm-related disorder, and preventing biofilm formation using polyamines is described.Type: ApplicationFiled: November 4, 2013Publication date: February 27, 2014Applicant: President and Fellows of Harvard CollegeInventors: Richard LOSICK, Illana KOLODKIN-GAL, Jon CLARDY, Shugeng CAO, Matt CABEEN, Roberto KOLTER, Liraz CHAI, Thomas BÖTTCHER
-
Publication number: 20130338098Abstract: A method for producing local analgesia in a subject having a site of local discomfort comprises administration of an aliphatic polyamine and, preferably, urea. A composition of the invention comprises an aliphatic polyamine and preferably urea. The polyamine can be an alkylamine, such as, preferably, putrescine. The composition can also include lidocaine and/or a copper containing component.Type: ApplicationFiled: March 13, 2013Publication date: December 19, 2013Applicant: Dermal Therapy (Barbados) Inc.Inventor: Dermal Therapy (Barbados) Inc.
-
Publication number: 20130190340Abstract: Certain aspects of the invention relate to compounds, compositions and methods that are useful for treating or preventing a disease in a subject by enhancing the degradation of a protein. In other aspects, said compounds can be useful research tools for investigating protein degradation. In other aspects, said compounds are useful research tools for investigating protein function. In certain embodiments, the degraded protein is implicated in a disease or disorder whose pathology is related at least in part to the excessive expression of the protein or the expression of a mutant form of the protein.Type: ApplicationFiled: June 30, 2011Publication date: July 25, 2013Applicant: Brandeis UniversityInventors: Lizbeth K. Hedstrom, Marcus Long, Deviprasad R. Gollapalli
-
Patent number: 8426474Abstract: Novel wash and carrier solutions ideally suited for topical administration (e.g., as wash solutions and as carrier solutions). The solutions described herein are non-toxic, non-irritating, isotonic, possess non-specific broad-spectrum antimicrobial properties, and have an alkaline pH. Also disclosed are sterile preparations of the solutions and methods of using the same.Type: GrantFiled: March 15, 2011Date of Patent: April 23, 2013Assignee: Teva Animal Health, Inc.Inventors: Richard Farng, Steven Mrha
-
Patent number: 8383682Abstract: A composition comprises surface-modified nanoparticles of at least one amphoteric metal oxide or oxyhydroxide. The nanoparticles bear, on at least a portion of their surfaces, a surface modification comprising (i) at least one surface modifier selected from lactate, thiolactate, and mixtures thereof, and (ii) at least one surface modifier selected from halide, nitrate, acetate, carbonate, formate, propionate, sulfate, bromate, perchlorate, tribromoacetate, trichloroacetate, trifluoroacetate, carboxylate comprising from one to about four alkyleneoxy moieties, chlorate, and mixtures thereof.Type: GrantFiled: December 16, 2008Date of Patent: February 26, 2013Assignee: 3M Innovative Properties CompanyInventor: Timothy D. Dunbar
-
Patent number: 8198334Abstract: Methods for modulating macrophage proliferation in an individual afflicted with or at risk for an ocular disease such as ARMD are provided. The methods employ a polyamine analog, or salt or protected derivative thereof. Macrophage proliferation has been implicated in a number of serious disorders, including ARMD. The invention also provides methods for aiding diagnosis and monitoring therapy of an ocular disease such as ARMD.Type: GrantFiled: February 22, 2005Date of Patent: June 12, 2012Assignee: Pathologica LLCInventor: Michael McGrath
-
Publication number: 20120015901Abstract: The present invention relates to a method of treating a life threatening condition in a critically ill human patient with a non-infectuous disorder, wherein the critically ill patient is a patient receiving enteral or parenteral nutrition, the method comprising the step of administering to said patient an autophagy inducing agent.Type: ApplicationFiled: July 13, 2011Publication date: January 19, 2012Applicants: Katholieke Universiteit Leuven, K.U.Leuven R&D, Joanneum Research Forschungsgesellschaft mbH, University of GrazInventors: Joris Winderickx, Greet Van Den Berghe, Jan Gunst, IIse Vanhorebeek, Lies Langouche, Tobias Eisenberg, Frank Madeo, Christophe Magnes, Frank Sinner
-
Patent number: 8084505Abstract: The present invention provides: a carbon nanohorn composite including a carbon nanohorn, a substance encapsulated in the carbon nanohorn, and a polyamine adsorbed by chemical reaction firmly to a surface functional group present on the opening part on the surface of the carbon nanohorn, wherein the release amount and release rate of the encapsulated substance can be controlled using the difference in size, substituent or three-dimensional structure of the polyamine, which is used as a plug; a method of controlling the release of the encapsulated substance; and a process for producing the carbon nanohorn composite. The release amount and release rate of the substance encapsulated in the carbon nanohorn composite is controlled by selecting a polyamine molecule, which plugs the opening part formed in the carbon nanohorn by oxidation, by its size, substituent or three-dimensional structure.Type: GrantFiled: July 3, 2007Date of Patent: December 27, 2011Assignee: NEC CorporationInventors: Ryota Yuge, Hideki Yorimitsu, Masako Yudasaka, Sumio Iijima
-
Publication number: 20110290693Abstract: Therapeutic compositions, devices and protocols for the treatment of keloids and other abnormal scars with improved appearance and a much lower recurrence rate. A therapeutic drug delivery device comprises an injectable mixture of a fibroblast inhibitor such as corticosteroid and a slow release carrier such as milled gel sponge dispersed in a fluid medium such as biological saline. The composition can be injected perilesionally in the dermis following excision of the keloid or other scar tissue, to circumscribe the wound. The infiltration of the mixture around the wound can provide a slow release of the fibroblast inhibitor for an extended period of time until normal wound closure can dominate and keloid or abnormal scar recurrence is inhibited.Type: ApplicationFiled: May 30, 2011Publication date: December 1, 2011Inventor: Canaan Vernon Lavelle Harris
-
Publication number: 20110280921Abstract: The present invention relates to hydrogels endowed with antibacterial properties, to be used for injection in damaged bones or in the production of antibacterial coatings of prostheses for implant in the human or animal body, obtained by loading with antibacterial agents hydrogels formed by derivatives of hyaluronic acid; the invention also relates to a kit of parts for producing the antibacterial hydrogels.Type: ApplicationFiled: January 29, 2010Publication date: November 17, 2011Applicants: NOVAGENIT S.R.L., MERO S.R.LInventors: Gaetano Giammona, Giovanna Pitarresi, Fabio Palumbo, Carlo Luca Romano, Enzo Meani, Edgardo Cremascoli
-
Patent number: 7994213Abstract: Disclosed are a coating agent for drug releasing stents, a method for preparing the same and a drug releasing stent coated therewith. The coating agent for drug releasing stents comprises nanoparticles with a biologically active material entrapped therein, wherein the particles are formed of a polyethyleneimine (PEI)-deoxycholic acid (DOCA) polymer (PDo) in which 1˜8 moles of DOCA are grafted per mole of PEI.Type: GrantFiled: May 28, 2008Date of Patent: August 9, 2011Assignees: Taewoong Medical Co., Ltd., Kyong-Min ShinInventors: Kyong-Min Shin, Dong-ki Lee, Don-haeng Lee, Kun Na, Eun-ae Jo
-
Publication number: 20110152213Abstract: It has been discovered that certain natural mRNAs serve as metabolite-sensitive genetic switches wherein the RNA directly binds a small organic molecule. This binding process changes the conformation of the mRNA, which causes a change in gene expression by a variety of different mechanisms. Modified versions of these natural “riboswitches” (created by using various nucleic acid engineering strategies) can be employed as designer genetic switches that are controlled by specific effector compounds. Such effector compounds that activate a riboswitch are referred to herein as trigger molecules. The natural switches are targets for antibiotics and other small molecule therapies.Type: ApplicationFiled: February 23, 2011Publication date: June 23, 2011Inventors: Ronald R. Breaker, Ali Nahvi, Narasimhan Sudarsan, Margaret S. Ebert, Wade Winkler, Jeffrey E. Barrick, John K. Wickiser
-
Publication number: 20110098284Abstract: The present invention provides a method of treating or preventing pain, inflammation or fever comprising administering to a subject in need of such treatment or prevention a therapeutically effective amount of one or more selected NSAIDs, in racemic, enantiomeric excess, or enantiomeric form, in combination with ethylenediamine and/or piperazine.Type: ApplicationFiled: April 28, 2006Publication date: April 28, 2011Inventor: Najib Babul
-
Publication number: 20110091586Abstract: The present invention features compositions comprising at least one compound of the formula I or formula II: wherein R1, R2, R3, R4, and R5 independently, are selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 hydroxyalkyl, or a cosmetically acceptable salt thereof, and the use thereof.Type: ApplicationFiled: November 30, 2010Publication date: April 21, 2011Inventors: Michael Southall, Katharine Martin, Phyllis Mitchell, Menas Kizoulis, Neena Tierney, Elvin R. Lukenbach, Binoy K. Bordoloi
-
Patent number: 7928147Abstract: Novel wash and carrier solutions ideally suited for topical administration (e.g., as wash solutions and as carrier solutions). The solutions described herein are non-toxic, non-irritating, isotonic, possess non-specific broad-spectrum antimicrobial properties, and have an alkaline pH. Also disclosed are sterile preparations of the solutions and methods of using the same.Type: GrantFiled: April 11, 2003Date of Patent: April 19, 2011Assignee: Teva Animal Health, Inc.Inventors: Richard Farng, Steven Mrha
-
Publication number: 20110082076Abstract: Microparticle compositions comprising metal ion-lipid complexes for drug delivery are described including methods of making the microparticle compositions and methods of treating certain conditions and disease states by administering the microparticle compositions. The metal ion-lipid complexes can be combined with various drugs or active agents for therapeutic administration. The microparticle compositions of the present invention have superior stability to other microparticle compositions resulting in a microparticle composition with longer shelf life and improved dispersability. The microparticle compositions of the present invention have a transition temperature (Tg) of at least 20° C. above the recommended storage temperature (Tst) for drug delivery.Type: ApplicationFiled: December 14, 2010Publication date: April 7, 2011Applicant: NOVARTIS AGInventors: Luis A. Dellamary, Jean Riess, Ernest G. Schutt, Jeffry G. Weers, Thomas E. Tarara
-
Patent number: 7919647Abstract: This invention provides a class of androgen receptor targeting agents. The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM).Type: GrantFiled: February 16, 2006Date of Patent: April 5, 2011Assignee: University of Tennessee Research FoundationInventors: James T. Dalton, Duane D. Miller, Yali He, Donghua Yin
-
Publication number: 20110034556Abstract: Human skin is treated for cosmetic purposes, in particular for the management of skin irritation and/or inflammation as well as inhibiting ageing effects, which result therefrom by using a topical cream containing at least one transglutaminase inhibitor such as putrescine.Type: ApplicationFiled: November 27, 2008Publication date: February 10, 2011Inventor: Kenneth Nicholis Dolynchuk
-
Patent number: 7871602Abstract: The use of bis-amines to enhance the antimicrobial activity of pharmaceutical compositions is described. The bis-amines are particularly useful for enhancing the antimicrobial activity of aqueous ophthalmic compositions, such as artificial tears or ocular lubricants, and solutions for disinfecting contact lenses.Type: GrantFiled: October 3, 2008Date of Patent: January 18, 2011Assignee: Alcon, Inc.Inventors: Nissanke L. Dassanayake, Thomas Christopher Carey, Ronald L. Schlitzer, David L. Meadows
-
Publication number: 20100286270Abstract: Germicidal compositions containing one or more N,N-bis(3-aminopropyl) C6-C18 alkyl amines, such as N,N-bis(3-aminopropyl)dodecylamine, and methods of using the compositions for treatment or prevention of infectious hoof diseases are disclosed. The germicidal compositions remain active in the presence of manure, which eliminates the need to pre-clean the hooves before use, and have particular utility for treating or preventing papillomatous digital dermatitis, interdigital phlegmon, interdigital dermatitis, laminitis, white line disease, heel erosion and other hoof diseases.Type: ApplicationFiled: September 10, 2007Publication date: November 11, 2010Applicant: DELAVAL HOLDINGS ABInventors: Chris Foret, Alex Skender, Thomas C. Hemling
-
Patent number: 7829543Abstract: Disclosed are methods of treating bacterial infections including those caused by multidrug resistant bacteria using polyamine efflux pump inhibiting compounds, including for example N-benzylated polyazaalkanes, N-benzylated polyaminoalkanes, or mixed N-benzylated poly(aza/amino)alkanes, optionally in combination with other drugs such as antibiotics, as well as pharmaceutical compositions thereof.Type: GrantFiled: January 7, 2004Date of Patent: November 9, 2010Assignee: Paratek Pharmaceuticals, Inc.Inventors: Mark L. Nelson, Michael N. Alekshun
-
Patent number: 7767860Abstract: Disclosed herein are substituted amino alcohol anti-mycobacterial agents and/or chelation therapy agents of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.Type: GrantFiled: September 3, 2008Date of Patent: August 3, 2010Assignee: Auspex Pharmaceuticals, IncInventors: Thomas G. Gant, Sepehr Sarshar
-
Publication number: 20100179368Abstract: The present invention relates generally to chemical and biological decontamination solutions and methods of using them. The invention is useful for decontaminating a wide range of compounds and organisms. In particular, the systems, methods, solutions, and formulations of the invention can be used to remove and/or neutralize organophosphates and other toxic chemicals, bacteria, bacterial spores, fungi, molds and viruses.Type: ApplicationFiled: September 25, 2009Publication date: July 15, 2010Applicant: Aries Associates, Inc.Inventor: Michael J. Conrad
-
Publication number: 20100158818Abstract: The present application relates to N-chlorinated cationic compounds of Formula I or a salt thereof, and associated compositions and methods of use as antimicrobial agents.Type: ApplicationFiled: November 6, 2009Publication date: June 24, 2010Inventors: Rakesh K. Jain, Eddy Low, Charles Francavilla, Timothy P. Shiau, Satheesh K. Nair
-
Publication number: 20100093868Abstract: Disclosed are a water-soluble metal-processing agent and a coolant both of which have excellent microbial deterioration resistance and are less likely to go rotten, a method for preparing the agent or the coolant, and a metal processing method. The water-soluble metal-processing agent or the coolant comprises an N,N,N?,N?-tetraalkyldiamine compound. The metal processing method is characterized by processing a metal of interest by using the water-soluble metal-processing agent or the coolant.Type: ApplicationFiled: September 21, 2007Publication date: April 15, 2010Applicant: YUSHIRO CHEMICAL INDUSTRY CO., LTD.Inventors: Toru Kadokawa, Akio Saito
-
Publication number: 20090325975Abstract: The present invention refers to the use of compounds active on the sigma receptor for the production of a medicament for the treatment of diabetes-associated pain.Type: ApplicationFiled: July 27, 2006Publication date: December 31, 2009Inventor: Helmut H Buschmann
-
Publication number: 20090317357Abstract: Methods for treating or preventing an autoimmune disease using agents that block the histamine H1 receptor are disclosed. H1 receptor-blocking agents useful in accordance with the methods provided herein include, for example, H1 antihistamines, particularly H1 antihistamines that do not substantially block the serotonin receptor.Type: ApplicationFiled: February 24, 2004Publication date: December 24, 2009Inventors: Lawrence Steinman, Rosetta Pedotti
-
Patent number: 7576135Abstract: A compound represented by formula (1): Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4??(1) [wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 represents the following group: (wherein Q5 is an alkylene group having 1 to 8 carbon atoms, or the like); and T0 and T1 are carbonyl groups or the like], a salt thereof, a solvate thereof, or an N-oxide thereof.Type: GrantFiled: December 25, 2003Date of Patent: August 18, 2009Assignee: Daiichi Pharmaceutical Co., Ltd.Inventors: Toshiharu Ohta, Satoshi Komoriya, Toshiharu Yoshino, Kouichi Uoto, Yumi Nakamoto, Hiroyuki Naito, Akiyoshi Mochizuki, Tsutomu Nagata, Hideyuki Kanno, Noriyasu Haginoya, Kenji Yoshikawa, Masatoshi Nagamochi, Syozo Kobayashi, Makoto Ono
-
Publication number: 20090192173Abstract: Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis. In certain embodiments, the present invention comprises compositions comprising novel substituted ethylene diamine compounds further comprising antitubercular agents such as rifampicin, isoniazid, pyrazinamide and ethambutol.Type: ApplicationFiled: October 22, 2008Publication date: July 30, 2009Inventors: Marina Nikolaevna PROTOPOPOVA, Leo Einck, Boris Nikonenko, Ping Chen
-
Patent number: 7445771Abstract: The use of bis-amines to enhance the antimicrobial activity of pharmaceutical compositions is described. The bis-amines are particularly useful for enhancing the antimicrobial activity of aqueous ophthalmic compositions, such as artificial tears or ocular lubricants, and solutions for disinfecting contact lenses.Type: GrantFiled: December 9, 2004Date of Patent: November 4, 2008Assignee: Alcon, Inc.Inventors: Nissanke L. Dassanayake, Thomas Christopher Carey, Ronald L. Schlitzer, David L. Meadows
-
Publication number: 20080234387Abstract: The invention relates to novel biocidal active substance mixtures containing o-phenylphenol and amines, methods for the production thereof the use thereof for protecting technical materials and products from being infested and destroyed by microorganisms, and microbicidal agents based on said novel mixtures.Type: ApplicationFiled: October 6, 2006Publication date: September 25, 2008Applicant: LANXESS DEUTSCHLAND GMBHInventors: Peter Wachtler, Martin Kugler
-
Publication number: 20080227767Abstract: Methods and compositions which are useful in the treatment of amyloidosis. In particular, methods and compositions are provided for inhibiting, preventing and treating amyloid deposition, e.g., in pancreatic islets, wherein the amyloidotic deposits are islet amyloid polypeptide (IAPP)-associated amyloid deposition or deposits. The methods of the invention involve administering to a subject a therapeutic compound which inhibits IAPP-associated amyloid deposits. Accordingly, the compositions and methods of the invention are useful for inhibiting IAPP-associated amyloidosis in disorders in which such amyloid deposition occurs, such as diabetes.Type: ApplicationFiled: May 22, 2008Publication date: September 18, 2008Applicant: Neurochem (International) LimitedInventors: Walter A. Szarek, Donald F. Weaver, Xianqi Kong, Ajay Gupta, David Migneault
-
Patent number: 7388112Abstract: The synthesis and use of a novel class of tumor necrosis factor (TNF?) inhibitors and immunomodulators are provided. Examples are those having the structures: wherein a, b and c are integers from 0 to 12, X equals NH or CHNH2, R1 and R2 each is a hydrogen or a C1 to C20 aliphatic; aliphatic amine; an alicyclic; aromatic; heterocycle; and halogenated forms thereof; and wherein, a, b and c are integers from 0 to 12; R1, R2, R3, and R4 each is a hydrogen or a C1 to C20; aliphatic amine; an alicyclic; aromatic; a heterocycle; and halogenated forms thereof.Type: GrantFiled: July 1, 2005Date of Patent: June 17, 2008Assignee: MediQuest Therapeutics, Inc.Inventors: Mark R. Burns, Maralee McVean, Kevin Kennedy, Arthur Yeung, Bruce H. Devens
-
Patent number: 7374770Abstract: Polyethylene glycol ethers of alkyl alcohols having the general formula CH3(CH2)xCH2(OCH2CH2)nOH wherein x is 8 to 20 (of which ceteareth-20, steareth-20 and steareth-100 are preferred), poloxamer 185, poloxamer 407, N,N-dimethyl dodecylamine N-oxide, and mixtures thereof, are employed to increase follicular delivery and/or follicular residence time of certain water soluble ornithine decarboxylase inhibitors of which 2(difluoromethyl)-2,5-diamino pentanoic acid and its pharmaceutically acceptable salts, hydrates, optical enantiomers and racemic mixture are preferred.Type: GrantFiled: August 13, 2002Date of Patent: May 20, 2008Assignee: SkinMedica, Inc.Inventors: Joyce T. Chou, Prakash Parab
-
Publication number: 20080114072Abstract: N1,N4-bis(buta-1,3-dienyl)butane-1,4-diamine dihydrochloride (also referred to as MDL 72,527 and N,N?-di-2,3-butadienyl-1,4-butanediamine dihydrochloride), or salts or solvates thereof, its use as an antioxidant, its use in preventing and/or treating prostate cancer in male humans, and its use in reducing the concentration of reactive oxygen species in human prostate gland tissue or any other body tissue, and methods of making the compound thereof. Other methods include inhibiting acetyl polyamine oxidase in human prostate tissue or other human body tissue comprising administering a therapeutic amount of N,N?-bis(2,3-butadienyl)-1,4-butanediamine or a salt or solvate thereof to the human, and a method of determining oxidative stress in human prostate tissue or other human or animal body tissue comprising measuring a ratio of oxidized 2?,7?-dichlorodihydrofluorescein diacetate fluorescence:DNA fluorescence and hydroethidine dye fluorescence ex vivo or in vivo.Type: ApplicationFiled: May 3, 2007Publication date: May 15, 2008Inventors: Hirak S. Basu, Dawn R. Church, Patrick M. Woster, George Wilding
-
Publication number: 20080027009Abstract: A method of protecting skin enzymes from the harmful effects of a cosmetic cleansing preparation which comprises water and one or more anionic surfactants. The method comprises using a cleansing preparation which has a pH value of from 4 to 7 and an SCTE (Stratum Comeum Tryptic Enzyme) value, determined following application of the preparation to human skin and standardized to a value of 100 for tap water, of from 65 to 95. The preparation comprises (i) one or more acyl-/dialkylethylenediamines which reduce the CMC of the one or more anionic surfactants and (ii) a buffer system of citric acid and citrate ions.Type: ApplicationFiled: March 24, 2005Publication date: January 31, 2008Applicant: BEIERSDORF AGInventors: Andreas Schepky, Albrecht Doerschner, Ursula Holtzmann, Katrin Counradi, Stephan Ruppert
-
Patent number: 7307071Abstract: Materials and methods for treating certain cancers are described, preferably cancers that result from the up-regulation of the RAF-MEK-ERK pathway, and more preferably chronic myelogenous leukemia, and which cancer is preferably resistant to the inhibition of the Bcr-Abl tyrosine kinase, imatinib.Type: GrantFiled: December 3, 2002Date of Patent: December 11, 2007Assignee: Onyx Pharmaceuticals, IncInventors: John F. Lyons, Gideon Bollag
-
Publication number: 20070280890Abstract: Disinfectant systems and methods of disinfecting a surface for drying are disclosed. One system comprises a carrier for drying the surface and an anti-microbial component for disinfecting the surface. The ant-microbial component forms a film-free coating containing an organic halogen salt when the carrier evaporates from the surface.Type: ApplicationFiled: May 30, 2006Publication date: December 6, 2007Inventor: Joseph Frank Gravlee
-
Patent number: 7276538Abstract: The use of the polyamine known as spermidine, i.e., N-(3-aminopropyl) tetraminethylenediamine, as an active principle in the preparation of a composition for pharmaceutical or dietetic use in man for combating hair loss is disclosed.Type: GrantFiled: January 17, 2003Date of Patent: October 2, 2007Assignee: Giuliani S.p.A.Inventors: Fabio Rinaldi, Elisabetta Sorbellini, Valter Gatti, Danila Ingrid Marchioretto
-
Publication number: 20070203249Abstract: This invention relates to a process of treating/affecting cancers that are particularly susceptible to radiation therapy by administering to a host in need of such treatment an amino acid and radiation therapy.Type: ApplicationFiled: February 14, 2007Publication date: August 30, 2007Inventor: Leandro Carlos A. Cerchietti
-
Patent number: 7232846Abstract: The oral administration to genetically alcoholic rats (from the strain UChB of the University of Chile) of a compound selected from endogenic polyamines (putrescine, spermidine, spermine), 1,3-propanediamine, their pharmaceutically acceptable salts and solvates, and their bioprecursor amides, causes a significant reduction in the alcohol consumption. The activity lasts for some time after the treatment period. Besides, there is a virtually null disulfiram-like adverse effect, what constitutes an advantage over the unpleasant use of some anti-alcoholism agents, such as calcium cyanamide or disulfiram itself. Therefore, the compounds of the invention are useful for the preparation of medicaments for the therapeutic and/or prophylactic treatment of alcoholism in human beings.Type: GrantFiled: September 19, 2002Date of Patent: June 19, 2007Assignee: Garbil Pharma Investigacion Chile Ltda.Inventors: Norberto Bilbeny Lojo, Hernan Garcia Madrid